UNSPSC 51343827: Daclatasvir/Sofosbuvir

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class AM800. This VA Drug Class (AM800) classifies this compound as belonging to the group ANTIVIRALS.

UNSPSC 51343827 Daclatasvir/Sofosbuvir is a Commodity code that nominally covers hepatitis C antivirals, but recent state and local procurement activity under this code shows little direct alignment with that pharmaceutical category. The most recent opportunities posted to this code include naloxone and drug deactivation systems (Seminole County, Florida), first aid and rescue supplies for a fire department (City of Tampa), generic multi-source pharmaceuticals and OTC products through a cooperative purchasing vehicle (Minnesota Multistate Cooperative Purchasing Alliance), and a market-intelligence RFI regarding direct-to-manufacturer prescription programs (Texas Health and Human Services Commission). State and local issuers posting under this code span county health departments, municipal fire departments, state health agencies, and multi-state cooperative purchasing alliances. None of the recent solicitations directly procure daclatasvir/sofosbuvir or other hepatitis C direct-acting antivirals.

The code shows recent activity across Florida, Texas, Minnesota, and Oregon, with representation from health departments, fire-rescue divisions, and centralized state procurement offices. Representative recent opportunities include Seminole County's IFB for naloxone and drug deactivation systems (posted June 30, 2026, due July 26, 2026), the City of Tampa's sealed-bid procurement for fire-rescue medical and first aid supplies with a $700,000 estimated contract value and SLBE set-aside (posted March 25, 2026, due March 13, 2026), the Minnesota Multistate Cooperative Purchasing Alliance's RFP for generic multi-source pharmaceuticals and OTC products (due March 26, 2026), and the Texas Health and Human Services Commission's RFI seeking vendor capabilities for a direct-to-manufacturer prescription program (posted April 3, 2026). The code appears to function as a catch-all category for miscellaneous pharmaceutical and medical supplies purchases rather than a targeted vehicle for hepatitis C treatment procurement; firms pursuing this code should assess whether the mismatch between the code's nominal scope and actual buying activity reflects a cataloging error or an intentionally broad procurement taxonomy.